$EHC

Darby John Patrick sold $1.1M of EHC

Darby John Patrick (EVP, Gen Counsel & Secretary) sold 8,906 shares of Encompass Health Corp (EHC) at $125.95 ($1.12M total) on 2026-08-10.

Original reporting
SEC EDGAR · Darby John Patrick
Published Aug 11, 2026, 6:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 6:49 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EHC
Neutral
medium confidence
Mentioned
$EHC
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EHCNeutralLow
01

Why it matters

The newest disclosed fact is the Aug 10 open-market sale of 8,906 shares by the company’s EVP, Gen Counsel, and Secretary, with holdings after the sale of 75,041 shares.

02

Market read

Traders may note insider selling as a minor sentiment input, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The article does not state motivations, tax needs, or whether other related transactions occurred; absence of a 10b5-1 plan does not automatically imply information advantage.

Relevance 6/10Novelty 3/10Timing: filed Aug 11 after Aug 10 sale

Background

This is an SEC Form 4 insider transaction disclosure for Encompass Health Corp (EHC).

Company-level read

Ticker impact

$EHCNeutralMedium confidence
Context

Encompass Health Corp disclosed an insider open-market sale by EVP and Gen Counsel Darby John Patrick for 8,906 shares at $125.95.

Expected impact

Likely minimal near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

Form 4 provides transaction details (size, price, post-sale holdings) but no new company guidance, contracts, or operational developments.

Market effects

No clear sector read-through from a single routine insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification and may not reflect bearish expectations, especially when the filing lacks any accompanying negative company news.

Key entities

  • Encompass Health Corp

    US-listed healthcare services company subject of the Form 4 insider sale disclosure.

  • Darby John Patrick

    EVP, General Counsel, and Secretary who sold shares via an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EHCMed

Encompass Health Named Top SMidCap Pick by TD Cowen

TD Cowen analyst Ryan Langston reiterated Encompass Health (EHC) as a top small- and mid-cap pick after its strong Q2 FY2026 results. Adjusted EBITDA was $348M (+3% vs consensus), revenue $1.597B (+10%), and EPS $1.55. Same-store volume rose 2.8%. EHC raised FY2026 adjusted EBITDA guidance by $15M and authorized a $1B share repurchase.

$EHCMedAI 8/10

Encompass Health Lifts 2026 Outlook Amid Strong Q2

Encompass Health (EHC) reported Q2 results and raised 2026 guidance. Q2 revenue rose 9.6% to support adjusted EBITDA of $348 million (+9.2%) and adjusted EPS up 10.7%. Full-year 2026 net operating revenue is guided to $6.41B-$6.49B, adjusted EBITDA $1.365B-$1.395B, and adjusted EPS $6.02-$6.25.

$EHCMed

Encompass Health Q2 Earnings Call Highlights

Encompass Health (NYSE:EHC) discussed Q2 updates on an earnings call. It expects Medicare pricing impact of about 2.3% in Q4 and 2026 salary/wage growth of 3.5% to 4.0%. It cut the 2026 net provider-tax benefit to about $10M from ~$21M. The company opened new beds, raised its dividend to $0.21, repurchased shares, and issued $500M notes, with net leverage at 1.9x.

$EHCMed

Encompass Health (EHC) Is Up 12.7% After Raising 2026 Guidance And Completing Major Buyback Program – Has The Bull Case Changed?

Encompass Health (EHC) reported Q2 2026 net operating revenue of $1,597.4 million and net income of $153.9 million, with higher EPS year over year. The company raised full-year 2026 revenue guidance and completed a major share repurchase program, retiring nearly one-tenth of shares, and increased shareholder returns. The article also cites higher debt after 2034 notes.